Can a stronger eylea dose dry up wet AMD faster?
NCT ID NCT07434713
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looks at how well a higher dose (8mg) of the drug Aflibercept (Eylea) works in the first two months for people with wet age-related macular degeneration, a leading cause of vision loss. Researchers will track fluid changes in the retina and vision improvements in 50 participants. The goal is to see if this dose can quickly control the disease and possibly reduce how often injections are needed.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Aflibercept 8mg (Eylea) injection
- What this could lead to
- If successful, this could show that a higher dose of Aflibercept works quickly to dry retinal fluid and improve vision in wet AMD, potentially reducing injection frequency.
- What could go wrong
- This is a small, early observational study with only 50 participants. It does not compare against other doses or treatments, so results may not apply broadly. Risks include eye infection or inflammation from the injection.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AGE-RELATED MACULAR DEGENERATION (AMD) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Dept. of Ophthalmology, University Hospital, Inselspital
RECRUITINGBern, 3010, Switzerland
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can At-Home eye scans personalize wet AMD treatment?
- AI eye doctor: could a computer spot Blindness-Causing diseases faster than humans?
- Gene therapy injection aims to halt blinding eye disease
- Scientists track Long-Term safety of experimental AMD therapy
- AMD Patients' knowledge gaps revealed in new study
- Can a new eye drug cut injection frequency for AMD patients?